Sigachi Industries began as a single-product cellulose manufacturer and has spent three decades turning that one molecule into a widening platform - first by mastering every grade and application of microcrystalline cellulose (MCC), then by buying an API maker and launching an asset-light plant-operations business, each move designed to sell more things to the same pharmaceutical formulators. The recurring logic is simple: start with a core excipient that gets you into the customer’s factory, then add adjacent products that capture a larger share of that customer’s spending, while backward-integrating into raw materials and forward-integrating into services. Today the company runs five manufacturing sites, serves over 500 customers across more than 65 countries, and is the largest MCC producer in India and among the top five globally.
Business segments
Three engines built on the same customer base - a cellulose-excipient core that is the company’s foundation, a young API business that shares those customers, and a capital-light plant-operations service that runs other people’s factories.
1. Cellulose-based excipients: the original platform
Sigachi makes the invisible powders that hold tablets together and help them dissolve - roughly 60 specialised grades of MCC and related excipients sold to pharma, food, and cosmetics manufacturers in over 65 countries.
- One molecule, dozens of jobs - microcrystalline cellulose works as a binder, filler, and disintegrant in tablets and capsules, and the company tailors it into about 60 grades with particle sizes from 15 to 250 microns, using different drying technologies (fluid bed, spray, and spin flash) and blending it with ingredients like colloidal silicon dioxide and mannitol to meet specific customer recipes.
- The moat is regulatory paperwork - all three MCC manufacturing units hold Certificates of Suitability from the European Directorate for the Quality of Medicines, and the company has filed over 18 Type IV Drug Master Files with the USFDA; a new competitor cannot sell into regulated pharma markets without years of similar filings.
- Backward-integrated into its own raw material - the company manufactures alpha cellulose, the precursor to MCC, in-house, which gives it control over quality and cost; the refined wood pulp it starts with is imported entirely from FSC-certified suppliers in Switzerland, the US, Canada, and South Africa because none is available domestically.
- Capacity is concentrated, and growing fast - three plants at Hyderabad, Jhagadia, and Dahej together hold roughly 22,000 tonnes per annum of MCC capacity, with the Dahej unit sitting in a Special Economic Zone next to the port for tax benefits and lower freight; a 12,000-tonne expansion at Dahej-2 is under construction and a 1,800-tonne CCS (superdisintegrant) plant is progressing steadily, which will lift total excipient capacity to 30,000 tonnes.
- New launches feed the same customers - recent additions like PureCoat film coatings, UltraMod polymer blends, and the BaseBlend vitamin premix series are sold to the same formulators who already buy MCC, so the sales effort is incremental while the wallet share grows.
2. Active pharmaceutical ingredients: the wallet-expander
APIs are the therapeutically active molecules in a drug - roughly 60% of a formulator’s input cost - and Sigachi entered the business by acquiring an 80% stake in a USFDA-compliant manufacturer to sell into the same customer basket as its excipients.
- Bought, not built from scratch - the 2023 acquisition of Trimax Bio Sciences for ₹100 crore gave Sigachi an operational API plant in Raichur, Karnataka, with 100 kilolitres of installed capacity and existing approvals from the USFDA, EMEA, and WHO, so it could start shipping quickly rather than spending years on construction and audits.
- Regulatory entry is sequenced - the strategy is to serve non-regulated and semi-regulated markets first, then move into regulated markets where margins are higher (around 25% EBITDA); Trimax received its first European CEP for Metformin Hydrochloride in May 2025 and has filed for Propafenone Hydrochloride, with six more CEPs targeted.
- A dedicated R&D engine is being built - an API R&D centre in Hyderabad opened in mid-2025 with 32-35 scientists and up to USD 1 million in investment, designed to take molecules from lab scale to commercial batches and regulatory filings under one roof.
- Specialty APIs are the long bet - the company is developing a Cystic Fibrosis combination (Vanzacaftor, Tezacaftor, Deutivacaftor) with an estimated revenue potential of roughly ₹250 crore per annum starting from Q4 FY27, though the innovator patent on Vanzacaftor runs until 2039, so commercialisation depends on partnership deals.
3. Operations and maintenance services: the capital-light third leg
Sigachi runs other companies’ chemical plants for a fee - an asset-light business that requires no capex and generates steady revenue from multi-year contracts with large industrial players.
- Paid to operate, not to own - the company takes over the day-to-day running of complex process plants in speciality chemicals, petrochemicals, water treatment, and pharmaceuticals, covering everything from boilers and cooling systems to wastewater treatment and air pollution control.
- The client list is the credential - named partners include Gujarat Alkalies and Chemicals (GACL), Grasim Industries (Aditya Birla Group), ONGC Petro Additions, and Adani Solar Power; a 2021 contract with Grasim to run three chlorine-product plants was worth ₹20 crores over three years.
- Contract manufacturing adds a second revenue stream - under the GACL relationship, Sigachi also makes sodium chlorate, stable bleaching powder, and poly aluminium chloride on a contract basis, which turns the O&M division into a manufacturing partner rather than just a facilities manager.
Group structure and partners
Sigachi is the single listed Indian parent, with two overseas subsidiaries and two joint ventures in the Middle East that are building local manufacturing and distribution for its pharma and nutrition products.
- US and UAE subsidiaries handle exports - Sigachi US Inc., incorporated in Virginia in 2017, supports American customer demands, while Sigachi MENA FZCO, set up in Dubai in 2022, serves as the hub for Middle East expansion.
- Two joint ventures target the Gulf - Sigachi Arabia (75% Sigachi MENA, 25% Saudi National Projects Investment) plans to build a manufacturing facility in Riyadh within three years to serve Saudi Arabia and the GCC; Sigachi Global (75% Sigachi MENA, 25% iConsult, UAE) targets the UAE food and pharma market with estimated revenues of USD 54 million by 2029.
- Trimax is the only major subsidiary with a minority partner - Sigachi owns 80% of the API manufacturer Trimax Bio Sciences, with an agreement to potentially acquire the remaining 20% after three years; the minority interest on the balance sheet was ₹114 million as of FY24.
- A nanofiber partnership opens a new delivery format - in April 2025, Sigachi MENA signed an MoU with Czech nanotechnology firm Respilon Group to develop drug-delivery solutions using NUENEX® nanofiber technology, targeting invisible patch and powder-based pharmaceutical formats.